These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 23992326)

  • 1. Targeted therapies in upper gastrointestinal malignancies.
    Azzariti A; Silvestris N
    Curr Med Chem; 2014; 21(8):947. PubMed ID: 23992326
    [No Abstract]   [Full Text] [Related]  

  • 2. MET as a potential target for the treatment of upper gastrointestinal cancers: characterization of novel c-Met inhibitors from bench to bedside.
    Avan A; Maftouh M; Funel N; Ghayour-Mobarhan M; Boggi U; Peters GJ; Giovannetti E
    Curr Med Chem; 2014; 21(8):975-89. PubMed ID: 23992325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and Single Nucleotide Polymorphism of Poly (ADPRibose) Polymerase-1 in Gastrointestinal Tumours: Clinical Involvement.
    Martín-Guerrero SM; León J; Quiles-Perez R; Belmonte L; Martin-Oliva D; Ruiz-Extremera Á; Salmerón J; Muñoz-Gámez JA
    Curr Med Chem; 2017; 24(20):2156-2173. PubMed ID: 28302009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of forced expression of mutated K-RAS gene on gastrointestinal cancer cell lines and the IGF-1R targeting therapy.
    Matsunaga Y; Adachi Y; Sasaki Y; Koide H; Motoya M; Nosho K; Takagi H; Yamamoto H; Sasaki S; Arimura Y; Tokino T; Carbone DP; Imai K; Shinomura Y
    Mol Carcinog; 2017 Feb; 56(2):515-526. PubMed ID: 27312358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cathelicidin a potential therapeutic peptide for gastrointestinal inflammation and cancer.
    Chow JY; Li ZJ; Wu WK; Cho CH
    World J Gastroenterol; 2013 May; 19(18):2731-5. PubMed ID: 23687409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive factors to targeted treatment in gastrointestinal carcinomas.
    Silvestris N; Marech I; Brunetti AE; Azzariti A; Numico G; Cicero G; Delcuratolo S; De Luca R; Burz C; Lorusso V
    Cancer Biomark; 2014; 14(2-3):151-62. PubMed ID: 24878816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aldo-keto reductase 1B10 promotes development of cisplatin resistance in gastrointestinal cancer cells through down-regulating peroxisome proliferator-activated receptor-γ-dependent mechanism.
    Matsunaga T; Suzuki A; Kezuka C; Okumura N; Iguchi K; Inoue I; Soda M; Endo S; El-Kabbani O; Hara A; Ikari A
    Chem Biol Interact; 2016 Aug; 256():142-53. PubMed ID: 27417252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclooxygenase-2 in gastrointestinal malignancies.
    Nagaraju GP; El-Rayes BF
    Cancer; 2019 Apr; 125(8):1221-1227. PubMed ID: 30747998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapies and predictive markers in epithelial malignancies of the gastrointestinal tract.
    McIntire M; Redston M
    Arch Pathol Lab Med; 2012 May; 136(5):496-503. PubMed ID: 22229849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting dynamics of subclones of GI, liver and pancreatic cancers.
    Ziogas DE; Glantzounis G; Liakakos T; Roukos DH
    Expert Rev Gastroenterol Hepatol; 2016 Jul; 10(7):773-6. PubMed ID: 27143511
    [No Abstract]   [Full Text] [Related]  

  • 11. EGFR(s) in aging and carcinogenesis of the gastrointestinal tract.
    Nautiyal J; Kanwar SS; Majumdar AP
    Curr Protein Pept Sci; 2010 Sep; 11(6):436-50. PubMed ID: 20491625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Precision Medicine in Gastrointestinal Pathology.
    Wang DH; Park JY
    Arch Pathol Lab Med; 2016 May; 140(5):449-60. PubMed ID: 27128302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The lack of CD34 expression in gastrointestinal stromal tumors is related to cystic degeneration following imatinib use.
    Koh Y; Lee HE; Oh DY; Kim JH; Lee SH; Kim SH; Kim DW; Im SA; Kim TY; Heo DS; Kim WH; Bang YJ
    Jpn J Clin Oncol; 2012 Nov; 42(11):1020-7. PubMed ID: 22952296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular targets in GI malignancies - A pathologist's perspective.
    Pawar S; Sharma A
    Indian J Pathol Microbiol; 2021 Jun; 64(Supplement):S43-S51. PubMed ID: 34135137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of Gastrointestinal Stromal Tumour: Current Practices and Visions for the Future.
    Blay JY; Casali PG; Dei Tos AP; Le Cesne A; Reichardt P
    Oncology; 2015; 89(1):1-13. PubMed ID: 25720422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upper gastrointestinal malignancies: a new era in clinical colorectal cancer.
    Hawkes E; Chau I; Ilson DH; Cunningham D
    Clin Colorectal Cancer; 2009 Oct; 8(4):185-9. PubMed ID: 19822506
    [No Abstract]   [Full Text] [Related]  

  • 17. Gastrointestinal stromal tumors.
    Taneva I; Dimitrova V
    Khirurgiia (Sofiia); 2011; (1):39-47. PubMed ID: 23847801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting platelet-derived growth factor (PDGF) signaling in gastrointestinal cancers: preclinical and clinical considerations.
    Abdel-Rahman O
    Tumour Biol; 2015 Jan; 36(1):21-31. PubMed ID: 25394897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changing pathology with changing drugs: tumors of the gastrointestinal tract.
    Cervera P; Fléjou JF
    Pathobiology; 2011; 78(2):76-89. PubMed ID: 21677471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug repurposing identifies therapeutic agents for gastrointestinal stromal tumors.
    Thorne J
    Future Med Chem; 2014 Apr; 6(6):602. PubMed ID: 25028758
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.